[Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
In 48 postmenopausal breast cancer patients receiving an adjuvant therapy with 30 mg tamoxifen for 22 months on an average the effect of hormonal therapy on different immunologic parameters was examined and compared with an age-matched control group of breast cancer patients without hormonal therapy. Before beginning and after the end of tamoxifen treatment the following examinations were performed: Leucocyte Migrations-Inhibition-Test (LMI-Test) against autologous and homologous tumor and recall antigens, determination of the serum levels of tumor necrosis factor alpha, interleukin 2 and interferon alpha, as well as a determination of lymphocyte subsets (total T-, T-helper-, T-Suppressor- and natural killer cells) in the peripheral blood. Compared to the control group under a tamoxifen therapy the percentage of patients with a migration inhibition in the LMI-test increased, whereas the percentage of patients with an enhancement decreased. There were no changes concerning the LMI-reactivity against recall antigens as well as concerning the serum levels of the different cytokine and the differentiation of T-cell subsets compared to the control group. But we found an increase of natural killer cells. It can be discussed if the clinical effect of a tamoxifen treatment is possibly due to its immunological effect on the nk cell activity.
Mallmann
P
P
Universitäts-Frauenklinik, Bonn.
Krebs
D
D
D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D002464:Cell Migration Inhibition; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000187:drug effects; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D013629:Tamoxifen
Einfluss einer Tamoxifentherapie auf Parameter der zellvermittelten Immunität bei postmenopausalen Patientinnen mit Mammakarzinom.